MOWOOT earns First-Ever ‘FDA Breakthrough Device Designation’ for a Novel Non-Drug and Non-Invasive Therapy of Neurogenic Bowel Disorder
Breakthrough status for Intermittent Colonic Exo-peristalsis™ therapy will help provide timely access to this novel treatment for patients and providers in the US market The medical device company USMIMA S.L. (brand name MOWOOT), with headquarter in Barcelona (Spain), announced today that its first product “MOWOOT II Intestinal Transit Management System” has been granted the … Continued